Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Authors

Raphael J Landovitz
Sue Li
Beatriz Grinsztejn
Halima Dawood
Albert Y Liu
Manya Magnus, George Washington University
Mina C Hosseinipour
Ravindre Panchia
Leslie Cottle
Gordon Chau
Paul Richardson
Mark A Marzinke
Craig W Hendrix
Susan H Eshleman
Yinfeng Zhang
Elizabeth Tolley
Jeremy Sugarman
Ryan Kofron
Adeola Adeyeye
David Burns
Alex R Rinehart
David Margolis
William R Spreen
Myron S Cohen
Marybeth McCauley
Joseph J Eron

Document Type

Journal Article

Publication Date

11-1-2018

Journal

PLoS medicine / Public Library of Science

Volume

15

Issue

11

DOI

10.1371/journal.pmed.1002690

APA Citation

Landovitz, R., Li, S., Grinsztejn, B., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Hendrix, C., Eshleman, S., Zhang, Y., Tolley, E., Sugarman, J., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A., Margolis, D., Spreen, W., Cohen, M., McCauley, M., & Eron, J. (2018). Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.. PLoS medicine / Public Library of Science, 15 (11). http://dx.doi.org/10.1371/journal.pmed.1002690

Peer Reviewed

1

Open Access

1